At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GERN Geron
Market Closed 05-10 16:00:00 EDT
3.80
-0.08
-2.06%
盘后3.80
+0.000.00%
19:43 EDT
High3.95
Low3.75
Vol4.37M
Open3.92
D1 Closing3.88
Amplitude5.03%
Mkt Cap2.25B
Tradable Cap2.08B
Total Shares593.13M
T/O16.63M
T/O Rate0.80%
Tradable Shares546.16M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Geron Corp (GERN) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves and Financial Health
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.